Get started
Author

Esther Hian Li Chan

Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
2021 · Michael R. Bishop, Michael Dickinson, et al. · New England Journal of Medicine · 541
PDF
Spatially-resolved transcriptomics reveal macrophage heterogeneity and prognostic significance in diffuse large B-cell lymphoma
2024 · Min Liu, Giorgio Bertolazzi, et al. · Nature Communications · 54
PDF
Effective Killing of Acute Myeloid Leukemia by TIM-3 Targeted Chimeric Antigen Receptor T Cells
2021 · Wen-Hsin Sandy Lee, Zhiyong Ye, et al. · Molecular Cancer Therapeutics · 54
Real world experience of R‐CHOP with or without consolidative radiotherapy vs DA‐EPOCH‐R in the first‐line treatment of primary mediastinal B‐cell lymphoma
2019 · Esther Hian Li Chan, Liang Piu Koh, et al. · Cancer Medicine · 47
An ex vivo platform to guide drug combination treatment in relapsed/refractory lymphoma
2022 · Jasmine Goh, Sanjay De Mel, et al. · Science Translational Medicine · 39
Application of an ex-vivo drug sensitivity platform towards achieving complete remission in a refractory T-cell lymphoma
2020 · Sanjay de Mel, Masturah B. M. Rashid, et al. · Blood Cancer Journal · 37
PDF
Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study
2021 · Michael R. Bishop, Michael Dickinson, et al. · Blood · 15
Determinants of response to daratumumab in Epstein-Barr virus-positive natural killer and T-cell lymphoma
2021 · Nurulhuda Mustafa, Adina Huey Fang Nee, et al. · Journal for ImmunoTherapy of Cancer · 12
Targeting the DNA damage response in hematological malignancies
2024 · Sanjay De Mel, Ainsley Ryan Lee, et al. · Frontiers in Oncology · 10
PDF
Clinical impact of the cell-of-origin classification based on immunohistochemistry criteria and Lymph2Cx of diffuse large B-Cell lymphoma patients in a South-east Asian population: a single center experience and review of the literature
2019 · Joanne Lee, Susan Swee-Shan Hue, et al. · Expert Review of Hematology · 10
Unusual case of metachronous EBV‐associated B‐cell and NK/T‐cell lymphoma mimicking polymyositis‐diagnostic challenges and pitfalls
2013 · Esther H.L. Chan, Suat‐Jin Lu, et al. · American Journal of Hematology · 10
EZH2 modulates mRNA splicing and exerts part of its oncogenic function through repression of splicing factors in CML
2025 · Reinhard Brunmeir, Li Ying, et al. · Leukemia · 8
PDF
Patterns of Oncogene Coexpression at Single-Cell Resolution Influence Survival in Lymphoma
2023 · Michal Marek Hoppe, Patrick Jaynes, et al. · Cancer Discovery · 7
PDF
Central nervous system (CNS) prophylaxis in antiCD20-CHOP treated DLBCL at intermediate to high risk for CNS relapse: A systematic review and meta-analysis
2021 · Guiyi Ho, Cherie Tan, et al. · Critical Reviews in Oncology/Hematology · 6
Treatment outcomes of T and natural‐killer/T‐cell lymphoma with ifosfamide, carboplatin and etoposide chemotherapy
2022 · Tricia Tay, Nagavalli Somasundaram, et al. · Cancer Reports · 5
PDF
Systematic review and meta-analysis: CAR-T vs bispecific antibody as third or later-line therapy for follicular lymphoma
2025 · Lawrence Cheng Kiat Ng, Xiu Hue Lee, et al. · Blood Cancer Journal · 4
PDF
Abstract CT160: A phase I trial to evaluate allogeneic NKG2DL-targeting chimeric antigen receptor-grafted γδ T cells in subjects with advanced solid tumors or hematological malignancies (the ANGELICA Trial)
2024 · Joan Choo, Wee Kiat Tan, et al. · Cancer Research · 4
Prospective Clinical Validation of a Combinatorial Functional Precision Medicine Platform in Relapsed/Refractory Non-Hodgkin's Lymphoma
2025 · Rui Xue Lee, Masturah Bte Mohd Abdul Rashid, et al. · JCO Precision Oncology · 3
A proposed predictive mathematical model for efficient T-cell collection by leukapheresis for manufacturing chimeric antigen receptor T cells
2023 · Xinxin Huang, Gina Pei Ling Gan, et al. · Haematologica · 3
PDF
Digital Spatial Profiling of Immune Markers in R‐chop Treated Diffuse Large B‐cell Lymphoma Reveals a Dominant Prognostic Significance of M2 Macrophage Infiltration
2019 · A.D. Jeyasekharan, M.M. Hoppe, et al. · Hematological Oncology · 3
Manufacturing Characteristics and Early Outcomes of a Tandem aCD22-aCD19 CAR-T Therapy for Childhood and Adult Relapsed/Refractory Acute Precursor B Lymphoblastic Leukemia
2025 · Michaela Su-fern Seng, Shui Yen Soh, et al. · Transplantation and Cellular Therapy · 2
Evaluating the Comprehensive Geriatric Assessment Model As an Assessment Tool to Predict Chemotoxicity in Elderly Patients with Lymphoma
2024 · Xinjie Jonathan Tang, Joanne Shu Xian Lee, et al. · Blood · 2
PDF
Treatment Patterns in Patients with Mantle Cell Lymphoma: Updated Report of the Asia-Pacific Multinational Retrospective Registry Study
2023 · Hyungwoo Cho, Dok Hyun Yoon, et al. · Blood · 2
PDF
Clinical benefit of depth of response for relapsed/refractory multiple myeloma patients treated on clinical trials: retrospective analysis from two tertiary centres
2018 · Esther H. L. Chan, Dunnya De‐Silva, et al. · British Journal of Haematology · 2
PDF
A Phase I/II Trial of Anti-CD22/CD19 CAR-T Cell Therapy, CART2219.1, in Adult and Pediatric Relapsed/Refractory B-ALL
2026 · Michaela Su-fern Seng, Zexi Guo, et al. · Blood Cancer Discovery · 1
Works count: 88
Citation count: 887
H-index: 10
I10-index: 11
Year
Topic
Type